Abstract
Myoepithelial cells (MEs), which surround ducts and acini of the breast glands, exhibit an anti-invasive phenotype and form a natural border separating proliferating tumour cells of ductal carcinoma in situ (DCIS) from basement membrane (bm) and underlying stroma. Invasion requires penetration of these host cellular and extracellular matrix barriers. This destruction is caused by proteolytic activity of tumour cells and host bystander cells. There is substantial evidence that high concentrations of the urokinase plasminogen-activating system are conducive to tumour cell spread and metastasis. Prompted by the conspicuous absence of studies examining the role of the ME in breast cancer progression, we studied the expression of the urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor type-1 (PAI-1) in MEs of 60 DCIS samples. Our results show that nearly all MEs of DCIS and normal breast glands exhibit the uPAR antigen, whereas the PAI-1 antigen was mainly expressed in MEs of high-grade DCIS. In one intermediate DCIS numerous ducts showed an incomplete myoepithelial layer expressing uPAR and PAI-1. We conclude that uPAR in MEs may be necessary to attach them to the bm by uPAR/vitronectin (Vn) interaction. The strong expression of PAI-1, which is known to resolve the uPAR/Vn binding, may be involved in the detachment of MEs of DCIS. Although the role of PAI-1 acting as cell detachment factor could not be demonstrated in our study, we speculate that the loss of the anti-invasive ME layer in DCIS may be triggered by PAI-1 and could be an early sign of subsequent tumour cell infiltration.
MeSH Terms
Adult
Aged
Antigens, CD
Breast Neoplasms/genetics,pathology
Carcinoma, Intraductal, Noninfiltrating/genetics,pathology
Enzyme Precursors
Female
Humans
Middle Aged
Plasminogen Activator Inhibitor 1/biosynthesis
Plasminogen Activators/biosynthesis
RNA, Messenger/biosynthesis
Receptors, Cell Surface/biosynthesis
Receptors, Urokinase Plasminogen Activator
Serine Proteinase Inhibitors/biosynthesis
Urokinase-Type Plasminogen Activator
Chemicals
Antigens, CD
Enzyme Precursors
PLAUR protein, human
Plasminogen Activator Inhibitor 1
RNA, Messenger
Receptors, Cell Surface
Receptors, Urokinase Plasminogen Activator
Serine Proteinase Inhibitors
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hildenbrand R
Pathologisches Institut, Universitätsklinikum Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. ralf.hildenbrand@path.ma.uni-heidelberg.de
Arens N
References (23)
23 references, click to expand
-
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Am J Pathol. 1997 Apr;150(4):1231-44
PMID: 9094980
-
Intraductal carcinoma of the breast: follow-up after biopsy only.
Cancer. 1982 Feb 15;49(4):751-8
PMID: 6275978
-
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Histochem Cell Biol. 1998 Jul;110(1):27-32
PMID: 9681686
-
Ductal carcinoma in situ of the breast.
BMJ. 1998 Sep 12;317(7160):734-9
PMID: 9732345
-
The human myoepithelial cell is a natural tumor suppressor.
Clin Cancer Res. 1997 Nov;3(11):1949-58
PMID: 9815584
-
Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis.
Am J Pathol. 1999 Jan;154(1):61-6
PMID: 9916919
-
A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling.
J Cell Biol. 1999 Mar 22;144(6):1285-94
PMID: 10087270
-
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
J Cell Biol. 1999 Jul 12;146(1):149-64
PMID: 10402467
-
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Histopathology. 2000 Jun;36(6):499-504
PMID: 10849091
-
Interaction of vitronectin with collagen.
J Biol Chem. 1986 Dec 15;261(35):16698-703
PMID: 2430969
-
cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.
J Clin Invest. 1986 Dec;78(6):1673-80
PMID: 3097076
-
Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue.
Am J Pathol. 1987 Apr;127(1):182-90
PMID: 2952015
-
Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury.
Circ Res. 1993 Oct;73(4):671-80
PMID: 7690310
-
The structure of the urokinase-type plasminogen activator receptor gene.
Blood. 1994 Aug 15;84(4):1151-6
PMID: 8049431
-
Identification of the urokinase receptor as an adhesion receptor for vitronectin.
J Biol Chem. 1994 Dec 23;269(51):32380-8
PMID: 7528215
-
Prognostic classification of breast ductal carcinoma-in-situ.
Lancet. 1995 May 6;345(8958):1154-7
PMID: 7723550
-
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Electrophoresis. 1995 May;16(5):813-6
PMID: 7588568
-
Regulation of integrin function by the urokinase receptor.
Science. 1996 Sep 13;273(5281):1551-5
PMID: 8703217
-
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
J Cell Biol. 1996 Sep;134(6):1563-71
PMID: 8830783
-
The myoepithelial defense: a host defense against cancer.
Med Hypotheses. 1997 Jan;48(1):37-46
PMID: 9049988
-
The mammary myoepithelial cell--Cinderella or ugly sister?
Breast Cancer Res. 2001;3(1):1-4
PMID: 11250738
-
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
Cancer Cell. 2002 Jun;1(5):445-57
PMID: 12124174
-
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Thromb Haemost. 1997 Jul;78(1):285-96
PMID: 9198168